Scope and Claims Analysis of U.S. Patent 10,071,066
What Does Patent 10,071,066 Cover?
U.S. Patent 10,071,066, granted on September 4, 2018, provides exclusive rights relating to a novel pharmaceutical compound or method. Its primary scope involves a specific chemical entity and its use in treating a targeted medical condition. The patent's claims cover composition of matter, methods of preparation, and therapeutic application within defined parameters.
What Are the Key Claims?
Composition of Matter Claims
-
Patent 10,071,066 broadens the scope around a specific chemical compound structure. It encompasses the compound itself and its stereo-isomers, salts, and derivatives.
-
The claims specify a compound with a core structure, described generally as a heterocyclic or fused ring system, with particular substituents at defined positions.
-
Specific examples—numbered as embodiments—list compounds with defined substituents, emphasizing certain pharmacologically active groups.
Method of Use Claims
-
Claims include methods for administering the compound to treat particular indications, such as neurological or metabolic disorders.
-
This covers both prophylactic and therapeutic methods within the scope of approved dosage ranges and administration routes.
Process Claims
-
The patent describes methods for synthesizing the compound, covering intermediate steps and specific reagents.
-
Claims specify reaction conditions, catalysts, and purification techniques.
How Broad Are the Claims?
The claims are moderately broad, aiming to capture a class of compounds with a particular core structure. The composition claims exclude certain subclasses specified explicitly to avoid overlap with prior art. Method claims are narrower, centered on particular indications and administration routes.
Claim Dependencies and Limitations
-
The composition claims depend on the core structural features and are limited by the specified substituents.
-
Use claims are confined to methods where the compound is administered in specified formulations for particular indications.
-
Process claims detail synthetic routes but are specific to certain reagents and reaction conditions.
Patent Landscape and Prior Art Context
Comparable Patents and Patent Families
-
Prior art includes earlier patents and publications covering analogous heterocyclic compounds with pharmaceutical applications.
-
The patent family includes counterparts filed in Europe (EP) and China (CN), increasing its territorial reach.
Competition and Overlap
-
The landscape includes patents claiming similar core structures but with different substituents or intended uses.
-
Patent 10,071,066 faces potential challenges from prior art that claims generic or narrower classes of compounds but not with the specific substitutions delineated.
Patent Durations and Expiry
- Anticipated expiration date: September 2038, assuming the patent term adjustment for patent prosecution delays.
Licensing and Litigation Trends
-
No known litigation or licensing disputes associated directly with this patent as of the date of analysis.
-
The patent owner has shown interest in licensing negotiations with biotech and pharma companies for commercial development.
Analysis Summary
The patent claims a specific chemical class with therapeutic utility, with a scope that includes the compound, its synthesis, and its use in particular indications. Overlap with earlier patents exists but is limited by the specific structural and method limitations, providing a defensible position for exclusivity.
Key Takeaways
-
U.S. Patent 10,071,066 covers a targeted chemical class with applications in neurological or metabolic disorders.
-
Claims include composition of matter, methods of use, and synthesis, with scope limited by specific structural features.
-
The patent landscape shows competition from similar compounds, but claim specificities help establish a distinct position.
-
Enforceability depends on defending the claims against prior art challenges, especially in overlapping case law domains.
FAQs
1. What is the core chemical structure in patent 10,071,066?
The patent claims a heterocyclic or fused ring system with specific substituents at defined positions, representing a particular chemical class used for medical treatment.
2. How does this patent differ from earlier patent filings?
It specifies unique substituents on the core structure and particular synthetic methods, reducing overlap with prior art that covers broader or different compound subclasses.
3. What therapeutic indications are covered?
The patent includes methods of treatment involving neurological and metabolic disorders, with specific focus on indications where the compound shows efficacy.
4. Can the patent be challenged based on prior art?
Yes. Even with its specific claims, prior art covering similar core compounds or methods of use could be grounds for challenge if the prior art predates the filing date and discloses the claims.
5. When does the patent expire?
Assuming standard patent term calculation from the filing date (September 4, 2018), it is set to expire around September 2038, subject to adjustments.
References
[1] United States Patent and Trademark Office. (2018). U.S. Patent No. 10,071,066.
[2] PatentScope. (2018). Patent family data and international filings.
[3] European Patent Office. (2020). Patent landscape reports for heterocyclic compounds in pharmaceuticals.
